JLE

Hématologie

MENU

La mise au ban de la rémission avec récupération incomplète Volume 25, numéro 2, Mars-Avril 2019

  • [1] Othus M., Sekeres M.A., Nans S. Relative survival l following response to 7 + 3 versus azacitidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia. 2019;33:371-378.
  • [2] Walter R.B., Kantarjian H.M., Huang X. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010;28:1766-1771.
  • [3] Cheson B.D., Bennett J.M., Kopecky K.J. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.
  • [4] Cheson B.D., Greenberg P.L., Bennett J.M. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425.
  • [5] Dohner H., Estey E., Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.